MEI Pharma Inc.
Latest From MEI Pharma Inc.
Asia Deal Watch: MEI Partners ME-401 With Japan’s Kyowa Hakko Kirin, Following Chinese Deal With BeiGene
About a month after signing a development and commercialization partnership in China for its PI3K delta inhibitor, MEI signs a deal for Japanese rights to the compound with Kyowa Hakko Kirin. Cue and LG Chem partner to develop targeted T-cell therapies for cancer.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.
Merck adds to its immuno-oncology R&D heft with purchase of Rigontec, while Allergan will collaborate with Lyndra to produce once-weekly drugs for Alzheimer’s disease.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
- Therapeutic Areas
- Marshall Edwards Inc.
- North America
- Parent & Subsidiaries
- MEI Pharma Inc.
- Senior Management
Daniel P Gold, PhD, Pres. & CEO
Brian Drazba, CFO
Robert D Mass, MD, CMO
David Urso, SVP, Corp. Dev. & COO
- Contact Info
MEI Pharma Inc.
Phone: (61)(858) 369-7100
3611 Valley Centre Dr.
San Diego, CA 92130
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.